XBiotech Inc. (XBIT): Price and Financial Metrics
GET POWR RATINGS... FREE!
XBIT POWR Grades
- XBIT scores best on the Growth dimension, with a Growth rank ahead of 68.25% of US stocks.
- The strongest trend for XBIT is in Value, which has been heading down over the past 179 days.
- XBIT ranks lowest in Momentum; there it ranks in the 4th percentile.
XBIT Stock Summary
- The ratio of debt to operating expenses for XBIOTECH INC is higher than it is for about only 0.44% of US stocks.
- XBIT's price/sales ratio is 25.43; that's higher than the P/S ratio of 94.95% of US stocks.
- Revenue growth over the past 12 months for XBIOTECH INC comes in at -78.2%, a number that bests only 2.05% of the US stocks we're tracking.
- Stocks that are quantitatively similar to XBIT, based on their financial statements, market capitalization, and price volatility, are NRIX, NTLA, RVMD, RNA, and INBX.
- XBIT's SEC filings can be seen here. And to visit XBIOTECH INC's official web site, go to www.xbiotech.com.
XBIT Valuation Summary
- XBIT's price/sales ratio is 26; this is 453.19% higher than that of the median Healthcare stock.
- XBIT's price/sales ratio has moved NA NA over the prior 96 months.
Below are key valuation metrics over time for XBIT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XBIT | 2023-03-17 | 26.0 | 0.4 | -3.2 | 1.6 |
| XBIT | 2023-03-16 | 26.0 | 0.4 | -3.2 | 1.6 |
| XBIT | 2023-03-15 | 25.7 | 0.4 | -3.1 | 1.6 |
| XBIT | 2023-03-14 | 12.1 | 0.4 | -2.7 | 3.1 |
| XBIT | 2023-03-13 | 12.3 | 0.4 | -2.8 | 3.1 |
| XBIT | 2023-03-10 | 12.4 | 0.4 | -2.8 | 3.1 |
XBIT Growth Metrics
- The year over year cash and equivalents growth rate now stands at -3.36%.
- Its 2 year price growth rate is now at -58.56%.
- Its 5 year price growth rate is now at 62.32%.
The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 8.21 | -19.286 | -36.164 |
| 2022-06-30 | 11.049 | -16.661 | -26.767 |
| 2022-03-31 | 14.044 | 62.513 | -20.241 |
| 2021-12-31 | 18.394 | 69.445 | -17.414 |
| 2021-09-30 | 19.163 | 70.813 | -12.785 |
| 2021-06-30 | 25.193 | 81.698 | -12.05 |
XBIT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
- XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
- QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.
The table below shows XBIT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.071 | 0.391 | -0.195 |
| 2021-03-31 | 0.102 | 0.248 | -0.138 |
| 2020-12-31 | 0.124 | 0.215 | -0.116 |
| 2020-09-30 | 0.082 | 0.166 | 7.794 |
| 2020-06-30 | 0.070 | 0.188 | 10.040 |
| 2020-03-31 | 0.039 | 0.237 | 14.665 |
XBIT Stock Price Chart Interactive Chart >
XBIT Price/Volume Stats
| Current price | $3.35 | 52-week high | $9.58 |
| Prev. close | $3.26 | 52-week low | $3.00 |
| Day low | $3.25 | Volume | 12,300 |
| Day high | $3.49 | Avg. volume | 32,902 |
| 50-day MA | $3.79 | Dividend yield | N/A |
| 200-day MA | $4.13 | Market Cap | 101.97M |
XBiotech Inc. (XBIT) Company Bio
XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.
Latest XBIT News From Around the Web
Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableEvery investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So take... |
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)XBiotech ( NASDAQ:XBIT ) Third Quarter 2022 Results Key Financial Results Net loss: US$12.7m (loss widened by 288% from... |
Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyIf you want to know who really controls XBiotech Inc. ( NASDAQ:XBIT ), then you'll have to look at the makeup of its... |
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerINCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech’s candidate cancer treatment i |
XBIT Price Returns
| 1-mo | -4.29% |
| 3-mo | 8.77% |
| 6-mo | -9.95% |
| 1-year | -63.98% |
| 3-year | -65.50% |
| 5-year | -29.47% |
| YTD | -4.56% |
| 2022 | -68.46% |
| 2021 | -28.88% |
| 2020 | -16.15% |
| 2019 | 267.42% |
| 2018 | 28.93% |
Loading social stream, please wait...